{"groups":[{"description":"Placebo administered orally (PO) once daily (QD) through Week 24. Participants continued to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study.","id":"FG000","title":"Placebo"},{"description":"Baricitinib 2 milligram (mg) administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"FG001","title":"Baricitinib 2 mg"},{"description":"Baricitinib 4 mg administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"FG002","title":"Baricitinib 4 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"10"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"4"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"1"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"176"},{"comment":"Randomized to 4mg (N=11) but received 2mg due to moderate renal impairment were included in 4mg arm","groupId":"FG001","numSubjects":"174"},{"groupId":"FG002","numSubjects":"177"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"56"},{"groupId":"FG001","numSubjects":"38"},{"groupId":"FG002","numSubjects":"33"}],"type":"Rescue Week 16-24"},{"achievements":[{"groupId":"FG000","numSubjects":"144"},{"groupId":"FG001","numSubjects":"157"},{"groupId":"FG002","numSubjects":"158"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"17"},{"groupId":"FG002","numSubjects":"19"}],"type":"NOT COMPLETED"}],"title":"Treatment Period"},{"milestones":[{"achievements":[{"comment":"Participants from treatment who entered the post-treatment follow-up period.","groupId":"FG000","numSubjects":"19"},{"comment":"Participants from treatment who entered the post-treatment follow-up period.","groupId":"FG001","numSubjects":"9"},{"comment":"Participants from treatment and rescue who entered the post-treatment follow-up period.","groupId":"FG002","numSubjects":"20"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"20"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Follow Up"}],"preAssignmentDetails":"Participants who did not adequately respond (nonresponders) to study drug were eligible for rescue treatment with baricitinib 4 mg beginning at Week 16. Nonresponders were defined as lack of improvement of at least 20% in both tender joint count and swollen joint count at both Weeks 14 and 16 compared to baseline."}